title: Understanding and treating patients with alcoholic cirrhosis: an update.
abstract: Alcoholic cirrhosis represents the terminal stage of alcoholic liver disease (ALD) and one of the main causes of death among alcohol abusers. The aim of this review was to provide an update on alcoholic cirrhosis, with an emphasis on recent findings. Increased alcohol consumption in developing countries is expected to increase cirrhosis mortality. There is a need, therefore, to develop new approaches to the prevention of ALD, including more attention to co-factors that may increase risk of ALD (i.e., obesity and diabetes, chronic HCV infection, and smoking). Furthermore, a better understanding of the pathological mechanisms on the basis of alcohol cirrhosis represents a cornerstone in order to develop new pharmacological treatments. Inflammatory and immune responses along with oxidative stress and alterations in adipokine secretion might contribute in different ways to the evolution of alcohol-induced fibrosis/cirrhosis. As of this date, patients with severe alcoholic hepatitis with a Maddrey Discriminant Factor (MDF) 32 should be offered pentoxifylline and/or corticosteroids unless contraindications exist. For ambulatory patients, S-adenosylmethionine (SAMe) may be considered in a motivated patient with nutritional support. Current studies do not support use of anti-tumor necrosis factor (TNF)-alpha antibody. Finally, achieving total alcohol abstinence should represent the main aim in the management of patients affected by any stage of cirrhosis. In the last decades, several drugs able to increase abstinence and prevent alcohol relapse have been evaluated and some of them have obtained approval for alcohol dependence. Patients with alcoholic cirrhosis; however, are usually excluded from such treatments. A recent study demonstrated the efficacy and safety of baclofen in inducing and maintaining alcohol abstinence in cirrhotic alcohol-dependent patients with cirrhosis. All together the information available suggests the need of a multimodal approach in the clinical management of these patients.
authors.affiliation: Institute of Internal Medicine, Catholic University of Rome (GA, LL), Rome, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Addolorato
authors.forename: Marcia
authors.initials: M
authors.lastname: Russell
authors.forename: Emanuele
authors.initials: E
authors.lastname: Albano
authors.forename: Paul S
authors.initials: PS
authors.lastname: Haber
authors.forename: Jack R
authors.initials: JR
authors.lastname: Wands
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Leggio
mesh_terms: D000818:Animals; D032882:Comprehension; D006801:Humans; D008104:Liver Cirrhosis, Alcoholic / Q000175:diagnosis* / Q000523:psychology / Q000628:therapy*; D013695:Temperance / Q000523:psychology; D016896:Treatment Outcome